I'm guessing you're referring to Goldman's late and somewhat shady price target cut. They still have a Neutral rating btw, no Sell rating. Two of the reasons for the price target cut were addressed in the conf. call at JMP this week-Safety data looks good and fear of GILD getting Accelerated Approval status from the FDA would NOT mean INFI could not do the same. Back to the 20's.